Close Menu

NEW YORK(GenomeWeb) – Diagnostics firm Biodesix said this week that it is collaborating with Swiss proteomics firm Biognosys on companion diagnostic development.

The collaboration will use Biognosys' HRM mass spec technology to complement Biodesix's traditional MALDI-TOF approach to biomarker discovery and development, Paul Beresford, Biodesix's chief business officer, told GenomeWeb.

Specifically, the company aims to better understand the specific analytes underlying the MALDI-TOF mass spec signal comprising its tests, Beresford said.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Retraction Watch writes that a cancer researcher has had an eighth paper retracted.

Computational biologist James Taylor has died, according to Johns Hopkins University.

The Centers for Disease Control and Prevention is starting to test people for SARS-CoV-2 antibodies, according to the New York Times.

In PLOS this week: features of tumor-infiltrating immune cells, regulatory effects of SNPs associated with prostate cancer risk, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.